Market Access · Value Dossiers
The Case for
Reimbursement.
Global value dossiers and country-specific adaptations built on evidence, structured for the audience, and designed to hold up in negotiations.
AMCP+ HTA Ready
Overview
Your Evidence, Structured to Win
Value dossier development is the process of translating your clinical programme into a structured, evidence-based argument for reimbursement. A payer submission dossier is not a literature review — it is the commercial case for your therapy, built from the evidence your payers actually need and structured to answer the questions they will inevitably ask. Our team builds global value dossiers that work as both submission documents and negotiation tools. The most common dossier failure is architectural — a dossier that tells the right evidence story in the wrong structure for the reviewing agency will not achieve the outcome its underlying data could support.
- Evidence-first global value dossiers
- Country-specific market adaptations
- AMCP format for US managed care
- Evidence gap analysis before writing
What We Deliver
Capabilities Across Every Stage
Three integrated disciplines, delivered by senior specialists as one accountable programme.
Global & Country-Specific Dossiers
Global value dossier pharma development begins with an evidence audit — a systematic assessment of everything your programme has generated that is relevant to the payer decision. Global payer submissions require a core dossier that presents this evidence comprehensively and positions it accurately relative to current standards of care in each target market. Market access documentation must be current, internally consistent, and complete — a reviewer who finds a gap or contradiction loses confidence in the entire document. Payer evidence dossier development at Vigilare Biopharma ensures no evidence gap is left unacknowledged; where a gap exists, the risk it carries is quantified, not obscured.
AMCP & HTA Submissions
AMCP dossier preparation follows the current AMCP Format for Formulary Submissions, which provides US managed care organisations with a structured framework for evaluating new therapies. Our AMCP dossiers go beyond format compliance — they address the clinical and cost management challenges specific to the therapeutic area in the US managed care context. HTA value dossier submissions for NICE, HAS, IQWiG, and PBAC follow each agency's specific evidence and format requirements. Reimbursement submission documents for each market are produced with local expert input — comparator set, cost data, and outcome measures reflecting the specific healthcare environment of that country.
Evidence-Based Value Communication
Pharma value communication in a dossier context is evidence synthesis with a strategic architecture. The structure of a dossier shapes how a reviewer encounters your evidence; a well-structured dossier leads the reviewer to your conclusions before they finish reading. Clinical economic dossier sections are built around a clear value story: unmet need, clinical differentiation, economic impact, and patient perspective. Product value demonstration through dossier content and payer advisory board testing is an iterative process managed from evidence planning through to final submission. For sponsors requiring global value dossier services USA EU UK Canada — payer submission support worldwide.
AMCPFormat Expertise
5Global Regions
Global+ Local Adaptations
ISO 90012015 Quality System
Key Deliverables
What You Receive
Tangible, submission-ready outputs — not status updates.
Global Value Dossier
Structured, evidence-based document presenting the full clinical, economic, and humanistic case for your therapy.
Country-Specific Adaptations
Market-adapted versions incorporating local comparators, cost data, and payer-specific framing.
Evidence Gap Analysis
Systematic assessment of evidence strengths and gaps with prioritised recommendations.
AMCP Dossier
US payer-facing dossier prepared to current AMCP format for pharmacy and therapeutics committee review.
Why Vigilare
Why Sponsors Choose Vigilare
What sets this engagement apart from a generic vendor.
Evidence-First Architecture
Evidence-first dossier architecture — the structure of each dossier is designed around the evidence available and the agency receiving it, not around a standard template applied to all markets.
Country Expert Oversight
Country expert oversight for every market adaptation — each national dossier is reviewed by an advisor with direct experience of the target HTA body or payer organisation.
Upfront Gap Analysis
Evidence gap analysis conducted before dossier writing begins — gaps are identified while there is still time to address them, not discovered during payer technical review.
AMCP + HTA Capability
AMCP format expertise for US managed care submissions alongside European HTA dossier capability — a single team coordinating the global dossier suite without quality compromise in any market.
Who We Work With
Configured to Your Model
We engage differently depending on the function you already have in place.
Pre-Launch Teams
Challenge
Preparing for simultaneous payer submissions in multiple markets with limited time and resource
How We Help
Full dossier suite built and adapted to agreed timelines, coordinated across markets.
HTA-Bound Sponsors
Challenge
Need evidence synthesised and positioned for agency-specific submission requirements
How We Help
Dossiers structured around each HTA body's evidence standards with country expert oversight.
Formulary Teams
Challenge
Seeking reimbursement through hospital or health system formulary committee submissions
How We Help
Value communication adapted for formulary audiences — cost, clinical differentiation, and system-level budget impact.
FAQs
Value Dossier Development, Answered.
01
What is a value dossier in pharma?
A value dossier in pharma is a structured document that comprehensively presents the clinical, economic, and humanistic value of a therapy to payers, HTA bodies, and formulary committees. It synthesises all available evidence — clinical trial data, health economic models, quality of life data, and real-world evidence — into a coherent argument for reimbursement. The AMCP dossier format is widely used in the US; European HTA submissions follow agency-specific formats for NICE, HAS, IQWiG, and PBAC.
02
How to prepare AMCP dossier?
AMCP dossier preparation follows the AMCP Format for Formulary Submissions, structuring the document into sections covering product overview, disease and treatment background, clinical evidence, safety profile, economic evidence, and additional information. Effective AMCP dossiers go beyond template completion — they anticipate the questions a pharmacy and therapeutics committee will ask and provide the clinical and cost management evidence needed to answer them in the context of the US managed care environment.
Related Services
Complete the Access Strategy
Bundle this with the wider evidence and access programme — coordinated from one team.
Ready to build your dossier?
Speak to our team about your programme requirements. We respond within one business day.